Pharma BD Deal Intelligence

Novartis AG / Alcon Inc.

2010 · Acquisition/Merger · $51.6B · Complete

Novartis completed its full acquisition of Alcon for approximately $51.6 billion across multiple stages, having first acquired a 25% stake from Nestle in 2008, then the remaining 52% Nestle stake in 2010, and finally merging in the 23% minority shares in 2011, creating the global leader in eye care.

Key facts

• Announced Jan 04, 2010
• Closed Apr 08, 2011
• Deal value $51.6B
• Deal type Acquisition/Merger
• Therapeutic area Infectious Disease, Ophthalmology
• Indications Glaucoma, Allergic conjunctivitis, Cataracts, Refractive disorders, Dry eye disease
• Key assets Alcon surgical equipment (phacoemulsification, IOLs), Alcon vision care (contact lens solutions), Travatan (travoprost), Patanol (olopatadine), Vigamox (moxifloxacin ophthalmic), Systane lubricant eye drops, AcrySof intraocular lenses, INFINITI Vision System
• Mechanism Prostaglandin analog, Histamine H1 receptor antagonist, Fluoroquinolone antibiotic

← Browse all deals  ·  How we score deals